Drug Trials Snapshots – LAZCLUZE
LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. LAZCLUZE is administered as tablets that are taken by mouth once daily…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
